Electronic cigarettes have become a big business as many smokers have opted to choose them over the traditional variety. Lack of actual smoke and tar is a major positive, but being able to “smoke” them even where smoking is not allowed may lead to a greater overall intake of nicotine. Nevertheless, many people bought e-cigarettes as a smoking cessation tool that takes away some of the habit forming qualities of real cigarettes while keeping the ever-addictive nicotine.
CN Creative, Ltd. out of Manchester, UK has raised £2 million ($3.1 million) to help bring to market its Nicadex electronic inhaler for nicotine replacement therapy. The device, which delivers vaporized pharmaceutical-grade nicotine, looks to be very much like a typical e-cigarette, but will undergo clinical trials and is planned to be used as a part of a wider smoking cessation therapy approach.
From the press release:
Nicadex is similar in concept to the electronic cigarettes currently marketed to adult consumers by CN Creative and others, but with several key differences.
First, Nicadex will be tested in clinical trials and then submitted for regulatory review under the process used for other prescription NRT products, initially through the UK Medicines and Healthcare products Regulatory Agency (MHRA) and then through the US Food and Drug Administration (FDA) and other regulatory agencies.
Second, CNC intends to market the Nicadex electronic inhaler as a medically supervised NRT designed to reduce the harm caused by smoking and to help smokers quit as part of a comprehensive smoking cessation programme.
Third, the Nicadex electronic inhaler has been specially engineered and will be manufactured in the UK under the same stringent standards used for regulated medical products, and the pharmaceutical-grade nicotine solution it uses is being produced by CNC in its own UK-based cGMP facilities approved for the manufacture of prescription drugs.
Nicadex is a hand-held device that delivers purified nicotine to the user through the vaporisation of a pharmaceutical-grade solution of nicotine. A rechargeable lithium battery powers the vaporiser that instantly turns the nicotine solution into a vapour that is inhaled by the user. Many users report that the sensation of using the Nicadex device is similar to smoking, but the vapour contains no smoke and none of the carbon monoxide, tar or thousands of toxic impurities that make smoking tobacco products so damaging to health. In addition, since there is no smoke, there are no smoke by-products that can cause “second-hand” harm to others.
